JP2011173928A5 - - Google Patents

Download PDF

Info

Publication number
JP2011173928A5
JP2011173928A5 JP2011128592A JP2011128592A JP2011173928A5 JP 2011173928 A5 JP2011173928 A5 JP 2011173928A5 JP 2011128592 A JP2011128592 A JP 2011128592A JP 2011128592 A JP2011128592 A JP 2011128592A JP 2011173928 A5 JP2011173928 A5 JP 2011173928A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
dose
epothilone
pharmaceutical formulation
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011128592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011173928A (ja
Filing date
Publication date
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Priority claimed from US09/233,993 external-priority patent/US6302838B1/en
Application filed filed Critical
Publication of JP2011173928A publication Critical patent/JP2011173928A/ja
Publication of JP2011173928A5 publication Critical patent/JP2011173928A5/ja
Pending legal-status Critical Current

Links

JP2011128592A 1998-02-25 2011-06-08 癌処置のためのエポチロンの使用 Pending JP2011173928A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GB9803907.6 1998-02-25
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GB9803905.0 1998-02-25
GB9805936.3 1998-03-19
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
GB9805937.1 1998-03-19
US09/233,993 1999-01-19
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000533117A Division JP2002504511A (ja) 1998-02-25 1999-02-23 癌処置のためのエポチロンの使用

Publications (2)

Publication Number Publication Date
JP2011173928A JP2011173928A (ja) 2011-09-08
JP2011173928A5 true JP2011173928A5 (enExample) 2012-07-26

Family

ID=27451759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011128592A Pending JP2011173928A (ja) 1998-02-25 2011-06-08 癌処置のためのエポチロンの使用

Country Status (4)

Country Link
US (1) US6302838B1 (enExample)
JP (1) JP2011173928A (enExample)
AT (1) ATE483462T1 (enExample)
DE (1) DE69942827D1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US6489314B1 (en) * 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EE200300396A (et) * 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
PL207197B1 (pl) * 2001-02-27 2010-11-30 Novartis Ag Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową, kompozycja farmaceutyczna zawierająca to połączenie oraz zastosowanie połączenia
AU2002251067B2 (en) * 2001-03-19 2005-05-26 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20070203346A1 (en) * 2001-04-30 2007-08-30 Oregon State University Method for synthesizing epothilones and epothilone analogs
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
JP2005513167A (ja) * 2002-01-14 2005-05-12 ノバルティス アクチエンゲゼルシャフト エポシロン誘導体と代謝拮抗剤からなる組合せ
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
PL211114B1 (pl) * 2002-05-01 2012-04-30 Novartis Ag Zastosowanie pochodnej epotilonowej w leczeniu choroby nowotworowej
AU2003296878A1 (en) * 2002-05-20 2004-12-13 Kosan Biosciences, Inc. Methods to administer epothilone d
RU2379032C9 (ru) * 2002-06-10 2010-03-27 Новартис Аг Комбинации, включающие эпотилоны, и их фармацевтическое применение
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4791183B2 (ja) 2002-08-23 2011-10-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロン、その中間体、類似体の合成およびその使用
ATE350034T1 (de) * 2002-10-15 2007-01-15 Univ Louisiana State Verwendung von epothilone zur behandlung hyperparathyreoidismus
KR20060025141A (ko) * 2003-05-15 2006-03-20 아르퀼 인코포레이티드 Ｐ38의 억제제 및 이를 사용하는 방법
US20060205795A1 (en) * 2003-06-27 2006-09-14 David Parkinson Cancer treatment with epothilones
MXPA06002393A (es) * 2003-09-02 2006-06-20 Novartis Ag Tratamiento de cancer con epotilomas.
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7829560B2 (en) * 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
EP2258704A1 (en) * 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
ES2637592T3 (es) 2006-04-14 2017-10-13 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
AU2009322158A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. RAF inhibitors and their uses
KR20120013336A (ko) * 2009-03-25 2012-02-14 노파르티스 아게 약물 및 ｓｉＲＮＡ를 함유하는 제약 조성물
BR112012020113A2 (pt) 2010-02-12 2016-06-07 Pharmascience Inc compostos de ligação ao domínio iap bir
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP1186606B2 (de) 1995-11-17 2011-09-07 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate, ihre Herstellung und Verwendung
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use

Similar Documents

Publication Publication Date Title
JP2011173928A5 (enExample)
CA2856646C (en) Combination treatment of cancer
JP2014515373A5 (enExample)
JP2009102342A5 (enExample)
JP2018513188A5 (enExample)
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
JP2015512406A5 (enExample)
JP2012180381A5 (enExample)
MX2012007410A (es) Compuestos antivirales novedosos.
JP2014526503A5 (enExample)
NZ711179A (en) Oral formulations of deferasirox
JP2010521417A5 (enExample)
JP2010526101A5 (enExample)
JP2015522630A5 (enExample)
JP2017132791A (ja) 組み合わせ組成物
JP2013209384A5 (enExample)
JP2013516493A5 (enExample)
JP2016516773A5 (enExample)
JP2019218379A5 (enExample)
JP2018531605A5 (enExample)
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
JP2010538066A5 (enExample)
JP2016505050A5 (enExample)
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
JP2019507786A5 (enExample)